Literature DB >> 1506447

Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method.

K Schmidt1, G Lucignani, R M Moresco, G Rizzo, M C Gilardi, C Messa, F Colombo, F Fazio, L Sokoloff.   

Abstract

The effects of tissue heterogeneity on the estimation of regional cerebral glucose utilization (rCMRglc) in normal humans with [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) and positron emission tomography (PET) were compared with respect to the various kinetic models of the [18F]FDG method. The kinetic models were conventional homogeneous tissue models of the [18F]FDG method, with (4K Model) and without (3K Model) a rate constant to account for an apparent loss of [18F]2-fluoro-2-deoxy-D-glucose-6-phosphate ([18F]FDG-6-P), and a tissue heterogeneity model (TH Model). When either of the kinetic models designed for homogeneous tissues was applied to heterogeneous tissues, estimates of the rate constant for efflux of [18F]FDG from the tissue (k2*) and of the rate constant for phosphorylation of [18F]FDG (k3*) decreased as the duration of the experimental period was increased. When the 4K Model was used, estimates of the rate constant for the apparent dephosphorylation of [18F]FDG-6-P (k4*) were significantly greater than zero and fell with increasing duration of the experimental period. Although the TH Model included no term to describe an apparent dephosphorylation of [18F]FDG-6-P, the fit of the TH Model to the time course of total tissue radioactivity was at least as good as and often better than the fit of the 4K Model in the 120-min period following the pulse of [18F]FDG. Hence, the high estimates of k4* found in PET studies of less than or equal to 120 min can be explained as the consequence of measuring radioactivity in a heterogeneous tissue and applying a model designed for a homogeneous tissue; there remains no evidence of significant dephosphorylation of [18F]FDG-6-P in this time period. Furthermore, use of the 4K Model led to an overestimation of rCMRglc; whole-brain glucose utilization calculated with the 4K Model was greater than 20% higher than values usually obtained in normal humans by the model-independent Kety-Schmidt technique. rCMRglc was accurately estimated by the TH Model and, in experimental periods sufficiently long to minimize the effects of tissue heterogeneity, also by the original 3K Model of the deoxyglucose method.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506447     DOI: 10.1038/jcbfm.1992.114

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

1.  Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose.

Authors:  Setsu Sakamoto; Kazunari Ishii; Kayo Hosaka; Tetsuya Mori; Masahiro Sasaki; Etsuro Mori
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

2.  Effect of tissue heterogeneity on quantification in positron emission tomography.

Authors:  G Blomqvist; A A Lammertsma; B Mazoyer; K Wienhard
Journal:  Eur J Nucl Med       Date:  1995-07

Review 3.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

Review 4.  Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective.

Authors:  Jillian S Weissenrieder; Jeffrey D Neighbors; Richard B Mailman; Raymond J Hohl
Journal:  J Pharmacol Exp Ther       Date:  2019-04-18       Impact factor: 4.030

5.  Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves.

Authors:  M Reimold; W Mueller-Schauenburg; G A Becker; G Reischl; B M Dohmen; R Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-19       Impact factor: 9.236

Review 6.  Methodological considerations in quantification of oncological FDG PET studies.

Authors:  Dennis Vriens; Eric P Visser; Lioe-Fee de Geus-Oei; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

7.  Regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in conscious, young adult men: normal values, variability, and reproducibility.

Authors:  Shrinivas Bishu; Kathleen C Schmidt; Thomas Burlin; Michael Channing; Shielah Conant; Tianjiang Huang; Zhong-hua Liu; Mei Qin; Aaron Unterman; Zengyan Xia; Alan Zametkin; Peter Herscovitch; Carolyn B Smith
Journal:  J Cereb Blood Flow Metab       Date:  2008-05-21       Impact factor: 6.200

8.  Voxel-based estimation of kinetic model parameters of the L-[1-(11)C]leucine PET method for determination of regional rates of cerebral protein synthesis: validation and comparison with region-of-interest-based methods.

Authors:  Giampaolo Tomasi; Alessandra Bertoldo; Shrinivas Bishu; Aaron Unterman; Carolyn Beebe Smith; Kathleen C Schmidt
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-13       Impact factor: 6.200

9.  Wavelet denoising in voxel-based parametric estimation of small animal PET images: a systematic evaluation of spatial constraints and noise reduction algorithms.

Authors:  Yi Su; Kooresh I Shoghi
Journal:  Phys Med Biol       Date:  2008-10-03       Impact factor: 3.609

10.  Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.

Authors:  Nicolas A Karakatsanis; Yun Zhou; Martin A Lodge; Michael E Casey; Richard L Wahl; Habib Zaidi; Arman Rahmim
Journal:  Phys Med Biol       Date:  2015-10-28       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.